ABIVAX Société Anonyme
ABVX•NASDAQ•Healthcare•Biotechnology

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOMarc M. de Garidel
Founded2013
Employees69
CountryFrance
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyEUR - EUR
TypeStock

Contact Information

Websitewww.abivax.com
Phone33 1 53 83 09 63
Address
7-11 boulevard Haussmann Paris, 75009 France

Corporate Identifiers

CIK0001956827
CUSIP00370M103
ISINUS00370M1036
SIC2834

Leadership Team & Key Executives

Marc M. P. de Garidel M.B.A.
Chief Executive Officer and Director
Didier Blondel
EVice President, Chief Financial Officer and Board Secretary
Didier Scherrer Ph.D.
Chief Scientific Officer
Patrick Malloy
Senior Vice President of Investor Relations
Ida Hatoum
Chief People and Compliance Officer
Pierre Courteille M.B.A.
Chief Business Officer
Jerome Denis Ph.D.
Executive Vice President of Process Development and Manufacturing
Hema Keshava
Senior Vice President of Finance
Chris Rabbat Ph.D.
Vice President and Global Head of Medical Affairs
Kevin Shan Ph.D.
Vice President and Global Head of Biometrics